drugset / Trial / NCT05124925

Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.

NCT05124925

Phase 2 Completed 21 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments

Timeline

Start
2022-07-27
Primary completion
2024-06-26
Completion
2026-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ianalumab Monoclonal antibody 300 mg Subcutaneous

Indications